Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer

Abstract

Abstract:

ObjectiveTo detect the status of PIK3CA in triple-negative breast cancer （TNBC）， and to analyze the relationships between PIK3CA mutation and clinical features and its impact on prognosis.MethodsFrom January 1， 2016 to December 31， 2018， 50 patients with primary TNBC admitted to Xinxiang Central Hospital of Henan Province were collected. The PIK3CA mutation status was detected， and the relationships between PIK3CA mutation and clinical characteristics of patients with TNBC and its impact on prognosis were analyzed.ResultsPIK3CA gene mutation was detected in 9 of 50 TNBC patients， with a mutation frequency of 18.0%. H1047R mutation was found in 4 cases， E545K mutation in 3 cases and E542K mutation in 2 cases. PIK3CA gene mutation was not associated with age （χ²=3.55，P=0.060）， tumor location （χ²=1.01，P=0.315）， tumor size （χ²<0.01，P>0.999）， lymph node status （χ²=0.76，P=0.385）， clinical stage （χ²=0.65，P=0.420）， Ki-67 value （χ²<0.01，P>0.999）， P53 status （χ²=0.02，P=0.894） and human epidermal growth factor receptor-2 （HER-2） status （χ²=1.65，P=0.200）. Prognostic analysis showed that 3-year disease-free survival rates of wild-type PIK3CA patients was significantly higher than that of mutant PIK3CA patients （80.5%vs.11.1%，χ²=28.23，P<0.001）.ConclusionThe frequency of PIK3CA gene mutation is higher in TNBC patients. There is no correlation between PIK3CA mutation and clinicopathologic features in TNBC patients. PIK3CA gene mutation may be significantly associated with poor prognosis of TNBC patients.

Key words:Triple negative breast cancer,PIK3CA gene mutation,Prognosis

Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin. Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer[J]. Journal of International Oncology, 2023, 50(5): 263-267.

Figures/Tables3

临床特征	例数	百分比（%）
初诊年龄（岁）
≤50	28	56.0
>50	22	44.0
肿瘤位置
左乳	27	54.0
右乳	23	46.0
肿瘤组织学
浸润性导管癌	43	86.0
导管原位癌	1	2.0
浸润性小叶癌	2	4.0
其他	4	8.0
T分期
T₁	24	48.0
T₂	26	52.0
N分期
N₀	26	52.0
N₁	17	34.0
N₂	6	12.0
N₃	1	2.0
临床分期
Ⅰ	13	26.0
Ⅱ	30	60.0
Ⅲ	7	14.0
肿瘤大小（cm）
≤2	16	32.0
>2	34	68.0
淋巴结状态
转移	24	48.0
无转移	26	52.0
P53状态
-	26	52.0
+	24	48.0
Ki-67值
≤20%	14	28.0
>20%	36	72.0
HER-2状态
-	29	58.0
+	16	32.0
++	5	10.0

临床特征	例数	PIK3CA		χ²值	P值
临床特征	例数	野生型	突变型	χ²值	P值
年龄（岁）
≤50	28	26	2	3.55	0.060
>50	22	15	7	3.55	0.060
肿瘤部位
左乳	27	24	3	1.01	0.315
右乳	23	17	6	1.01	0.315
肿瘤大小（cm）
≤2	16	13	3	<0.01	>0.999
>2	34	28	6	<0.01	>0.999
淋巴结状态
无转移	26	23	3	0.76	0.385
转移	24	18	6	0.76	0.385
临床分期
Ⅰ~Ⅱ期	43	34	9	0.65	0.420
Ⅲ期	7	7	0	0.65	0.420
Ki-67值
≤20%	14	11	3	<0.01	>0.999
>20%	36	30	6	<0.01	>0.999
P53状态
-	26	22	4	0.02	0.894
+	24	19	5	0.02	0.894
HER-2状态
阴性	29	26	3	1.65	0.200
低表达	21	15	6	1.65	0.200

References16

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi:10.3322/caac.21660
[2]	Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress[J]. NPJ Breast Cancer, 2022, 8(1): 95. DOI: 10.1038/s41523-022-00468-0. doi:10.1038/s41523-022-00468-0pmid:35987766
[3]	Cho YA, Ko SY, Suh YJ, et al. PIK3CA mutation as potential poor prognostic marker in Asian female breast cancer patients who received adjuvant chemotherapy[J]. Curr Oncol, 2022, 29(5): 2895-2908. DOI: 10.3390/curroncol29050236. doi:10.3390/curroncol29050236pmid:35621626
[4]	Reinhardt K, Stückrath K, Hartung C, et al. PIK3CA-mutations in breast cancer[J]. Breast Cancer Res Treat, 2022, 196(3): 483-493. DOI: 10.1007/s10549-022-06637-w. doi:10.1007/s10549-022-06637-w
[5]	李瑛珏, 路丹. PI3K通路在肿瘤免疫微环境中的作用机制[J]. 国际肿瘤学杂志, 2022, 49(11): 677-680. DOI: 10.3760/cma.j.cn371439-20220612-00133. doi:10.3760/cma.j.cn371439-20220612-00133
[6]	Miricescu D, Totan A, Stanescu-Spinu Ⅱ, et al. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects[J]. Int J Mol Sci, 2020, 22(1): 173. DOI: 10.3390/ijms22010173. doi:10.3390/ijms22010173
[7]	Chen L, Yang L, Yao L, et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients[J]. Nat Commun, 2018, 9(1): 1357. DOI: 10.1038/s41467-018-03867-9. doi:10.1038/s41467-018-03867-9pmid:29636477
[8]	Deng L, Zhu X, Sun Y, et al. Prevalence and prognostic role of PIK3CA/AKT1 mutations in Chinese breast cancer patients[J]. Cancer Res Treat, 2019, 51(1): 128-140. DOI: 10.4143/crt.2017.598. doi:10.4143/crt.2017.598pmid:29540052
[9]	Jia M, Liao N, Chen B, et al. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing[J]. Breast Cancer, 2021, 28(3): 644-652. DOI: 10.1007/s12282-020-01199-5. doi:10.1007/s12282-020-01199-5pmid:33386585
[10]	陈本川. 治疗PIK3CA基因突变晚期乳腺癌新药——阿培利西(alpelisib)[J]. 医药导报, 2019, 38(11): 1528-1535. DOI: 10.3870/j.issn.1004-0781.2019.11.033. doi:10.3870/j.issn.1004-0781.2019.11.033
[11]	Xiao W, Zhang G, Chen B, et al. Mutational landscape of PI3K-AKT-mTOR pathway in breast cancer: implications for targeted therapeutics[J]. J Cancer, 2021, 12(14): 4408-4417. DOI: 10.7150/jca.52993. doi:10.7150/jca.52993pmid:34093841
[12]	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418): 61-70. DOI: 10.1038/nature11412. doi:10.1038/nature11412
[13]	Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers[J]. Nature, 2012, 486(7403): 395-399. DOI: 10.1038/nature10933. doi:10.1038/nature10933
[14]	Kriegsmann M, Endris V, Wolf T, et al. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequen-cing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences[J]. Oncotarget, 2014, 5(20): 9952-9965. DOI: 10.18632/oncotarget.2481. doi:10.18632/oncotarget.2481pmid:25296970
[15]	Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. doi:10.1016/j.ccell.2019.02.001
[16]	Guo S, Loibl S, von Minckwitz G, et al. PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy[J]. Cancer Res Treat, 2020, 52(3): 689-696. DOI: 10.4143/crt.2019.497. doi:10.4143/crt.2019.497pmid:32019278